Serum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer

Abstract Lung cancer continues to be the leading cause for cancer-related deaths in men and women worldwide. Sufficient screening tools enabling early diagnosis are essential to improve patient outcomes. The aim of this study was to evaluate serum midkine (S-MK) both as a diagnostic and prognostic b...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Louisa Stern, Erik Mueller, Eugen Bellon, Matthias Reeh, Rainer Grotelueschen, Cenap Guengoer, Nathaniel Melling, Mara Goetz, Daniel R. Perez, Jakob R. Izbicki, Tamina Rawnaq-Möllers, Tarik Ghadban
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/fcd36118818843c9954e6cffbcfe8aaa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fcd36118818843c9954e6cffbcfe8aaa
record_format	dspace
spelling	oai:doaj.org-article:fcd36118818843c9954e6cffbcfe8aaa2021-12-02T15:33:01ZSerum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer10.1038/s41598-021-94272-82045-2322https://doaj.org/article/fcd36118818843c9954e6cffbcfe8aaa2021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94272-8https://doaj.org/toc/2045-2322Abstract Lung cancer continues to be the leading cause for cancer-related deaths in men and women worldwide. Sufficient screening tools enabling early diagnosis are essential to improve patient outcomes. The aim of this study was to evaluate serum midkine (S-MK) both as a diagnostic and prognostic biomarker in non-small cell lung cancer (NSCLC). This single-center analysis included 59 NSCLC patients counting 30 squamous cell cancers and 29 adenocarcinomas. Preoperative S-MK concentration was determined using ELISA. Patients were followed up to five years. S-MK was found to be significantly overexpressed in patients with NSCLC compared to healthy controls (p < 0.001). The discriminative power of S-MK to differentiate NSCLC subjects from controls was fairly high with an area under the receiver operating characteristic curve of 0.83 (p < 0.001). Optimal sensitivity of 92% and reasonable specificity of 68% was reached at a threshold of 416 pg/ml S-MK. Patients with high S-MK concentration showed a significantly shorter overall survival compared to patients with low S-MK expression (p < 0.05). In conclusion, S-MK is overexpressed in patients with NSCLC and serves as an independent prognostic factor for overall survival. S-MK may thus be considered as an additional non-invasive biomarker not only for NSCLC screening but also for outcome prediction.Louisa SternErik MuellerEugen BellonMatthias ReehRainer GrotelueschenCenap GuengoerNathaniel MellingMara GoetzDaniel R. PerezJakob R. IzbickiTamina Rawnaq-MöllersTarik GhadbanNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Louisa Stern Erik Mueller Eugen Bellon Matthias Reeh Rainer Grotelueschen Cenap Guengoer Nathaniel Melling Mara Goetz Daniel R. Perez Jakob R. Izbicki Tamina Rawnaq-Möllers Tarik Ghadban Serum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer
description	Abstract Lung cancer continues to be the leading cause for cancer-related deaths in men and women worldwide. Sufficient screening tools enabling early diagnosis are essential to improve patient outcomes. The aim of this study was to evaluate serum midkine (S-MK) both as a diagnostic and prognostic biomarker in non-small cell lung cancer (NSCLC). This single-center analysis included 59 NSCLC patients counting 30 squamous cell cancers and 29 adenocarcinomas. Preoperative S-MK concentration was determined using ELISA. Patients were followed up to five years. S-MK was found to be significantly overexpressed in patients with NSCLC compared to healthy controls (p < 0.001). The discriminative power of S-MK to differentiate NSCLC subjects from controls was fairly high with an area under the receiver operating characteristic curve of 0.83 (p < 0.001). Optimal sensitivity of 92% and reasonable specificity of 68% was reached at a threshold of 416 pg/ml S-MK. Patients with high S-MK concentration showed a significantly shorter overall survival compared to patients with low S-MK expression (p < 0.05). In conclusion, S-MK is overexpressed in patients with NSCLC and serves as an independent prognostic factor for overall survival. S-MK may thus be considered as an additional non-invasive biomarker not only for NSCLC screening but also for outcome prediction.
format	article
author	Louisa Stern Erik Mueller Eugen Bellon Matthias Reeh Rainer Grotelueschen Cenap Guengoer Nathaniel Melling Mara Goetz Daniel R. Perez Jakob R. Izbicki Tamina Rawnaq-Möllers Tarik Ghadban
author_facet	Louisa Stern Erik Mueller Eugen Bellon Matthias Reeh Rainer Grotelueschen Cenap Guengoer Nathaniel Melling Mara Goetz Daniel R. Perez Jakob R. Izbicki Tamina Rawnaq-Möllers Tarik Ghadban
author_sort	Louisa Stern
title	Serum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer
title_short	Serum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer
title_full	Serum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer
title_fullStr	Serum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer
title_full_unstemmed	Serum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer
title_sort	serum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/fcd36118818843c9954e6cffbcfe8aaa
work_keys_str_mv	AT louisastern serummidkineasnoninvasivebiomarkerfordetectionandprognosisofnonsmallcelllungcancer AT erikmueller serummidkineasnoninvasivebiomarkerfordetectionandprognosisofnonsmallcelllungcancer AT eugenbellon serummidkineasnoninvasivebiomarkerfordetectionandprognosisofnonsmallcelllungcancer AT matthiasreeh serummidkineasnoninvasivebiomarkerfordetectionandprognosisofnonsmallcelllungcancer AT rainergrotelueschen serummidkineasnoninvasivebiomarkerfordetectionandprognosisofnonsmallcelllungcancer AT cenapguengoer serummidkineasnoninvasivebiomarkerfordetectionandprognosisofnonsmallcelllungcancer AT nathanielmelling serummidkineasnoninvasivebiomarkerfordetectionandprognosisofnonsmallcelllungcancer AT maragoetz serummidkineasnoninvasivebiomarkerfordetectionandprognosisofnonsmallcelllungcancer AT danielrperez serummidkineasnoninvasivebiomarkerfordetectionandprognosisofnonsmallcelllungcancer AT jakobrizbicki serummidkineasnoninvasivebiomarkerfordetectionandprognosisofnonsmallcelllungcancer AT taminarawnaqmollers serummidkineasnoninvasivebiomarkerfordetectionandprognosisofnonsmallcelllungcancer AT tarikghadban serummidkineasnoninvasivebiomarkerfordetectionandprognosisofnonsmallcelllungcancer
_version_	1718387181718863872

Serum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer

Ejemplares similares